Lignans are biphenolic compounds in plant foods with a structure similar to oestrogens. They are the major source of phyto-oestrogens in Western populations and are primarily present in fibre-rich foods (such as seeds, grains, vegetables, and fruits) ([@bib1]; [@bib28]). In the human gut, plant lignans are converted by intestinal bacteria to the enterolignans, enterolactone and enterodiol, which are bioactive and are subsequently absorbed ([@bib1]).

There are several mechanisms by which enterolignans may protect against cancer. They were shown to have weak oestrogenic activity and may bind to oestrogen receptors (ERs) ([@bib17]; [@bib21]). Moreover, they may exert effects via oestrogen receptor-independent mechanisms, such as inhibition of tumour growth and angiogenesis, as well as stimulation of apoptosis and of sex hormone-binding globulin production (SHBG) ([@bib2]; [@bib22]; [@bib1]; [@bib16]; [@bib26], [@bib25]).

Lignans have been associated with postmenopausal breast cancer risk; however, the results were inconsistent. Two recent meta-analyses found lignans to be associated with a small risk reduction only in postmenopausal but not in premenopausal women based on studies in Eastern and Western countries ([@bib32]; [@bib7]).

There is limited epidemiological evidence on the potential effects of lignans with respect to breast cancer prognosis. Two studies, conducted in the United States, assessed the association of dietary plant lignans with survival in postmenopausal breast cancer patients ([@bib8]; [@bib15]). One study reported that a higher dietary lignan intake was associated with a better prognosis ([@bib15]), whereas the other found no association ([@bib8]). Neither study examined the association of estimated enterolignans with survival.

Dietary fibre and a diet rich in fibre has been (inconsistently) associated with a better survival after breast cancer ([@bib11]; [@bib13]; [@bib12]). As lignans originate partly from fibre complex in foods, it is still unclear whether associations observed with fibre-rich foods are attributed to fibre or enterolignans or both.

Thus, we investigated the association of estimated amounts of enterolignans (enterolactone and enterodiol), dietary intake of lignan-rich foods (seeds, bread, vegetables, and fruit), and dietary fibre intake with overall and breast cancer-specific survival (BCSS) in a large German cohort of postmenopausal breast cancer patients. Furthermore, we examined whether this association is modified by hormone receptor status of the tumours and menopausal hormone therapy use at diagnosis.

Materials and methods
=====================

Study population
----------------

Our study population comprised breast cancer patients aged 50--74 years who participated in a population-based case--control study carried out in two German study regions (Hamburg and Rhein-Neckar-Karlsruhe (RNK)) ([@bib9]) and were followed up until the end of 2009. The patients were diagnosed with a histologically confirmed primary invasive or *in situ* breast tumour between 1 January 2001 and 30 September 2005 in Hamburg and between 1 August 2002 and 31 July 2005 in the RNK region and were identified through participating clinics and the Cancer Registry of Hamburg. Postmenopausal status was defined by one or more of the following criteria: last menstrual bleeding at least 12 months before diagnosis, bilateral oophorectomy, or \>55 years with unclear menopausal status due to hysterectomy or hormone use. We included 2668 postmenopausal patients who completed a food frequency questionnaire (FFQ) and did not have missing information on cancer before the breast cancer diagnosis and were not previously diagnosed with cancer (except for *in situ* carcinoma, and basal and squamous cell skin carcinoma).

At recruitment, in-person interviews were performed to collect information on demographic, anthropometric, socioeconomic, and lifestyle factors. Moreover, information on suggested and established breast cancer risk factors and possible prognostic factors was obtained. Clinical and pathological records were used to collect information on further prognostic factors.

The study was approved by the ethics committees of the University of Heidelberg, the University of Hamburg, and the Medical Board of the State of Rheinland-Pfalz, and conducted in agreement with the Helsinki declaration. All participants provided written informed consent at recruitment as well as during follow-up.

Dietary data
------------

At recruitment, a self-administered validated 176-items FFQ was completed by the patients, which recorded the nutritional habits one year before diagnosis. This FFQ was similar to the one used in the European Prospective into Cancer and Nutrition (EPIC) study, and nutrient intake (e.g., dietary fibre) was calculated using the German food composition table Bundeslebensmittelschluessel II.3 (Bundesinstitut für Gesundheitlichen Verbraucherschutz und Veterinärmedizin) ([@bib4], [@bib5]). For each food item, the information about portion size and consumption frequency was used to calculate intakes in grams per day (g day^--1^). The two enterolignans, enterolactone and enterodiol, were estimated from data on incubation with human faeces, in which the bioavailable enterolignans were calculated per 100 g of ingested foods ([@bib30]; [@bib14]).

Two lignan-rich food items, sunflower-/pumpkinseeds and sesame/flaxseeds, were added to the original EPIC-FFQ for this specific study. Mean daily intake in g day^--1^ was estimated for each food item.

A top and bottom energy cutoff of 0.5% was used, as the data were considered unreliable in extreme ranges of energy intake (energy range: 425--4577 kcal day^--1^), resulting in 2653 patients finally included in the statistical analyses.

Outcome definition
------------------

Vital status of all patients was ascertained via local population registries through the end of 2009, and causes of death were verified by death certificates and coded based on ICD-10 classifications. The end points of interest were overall survival (OS) and BCSS. The OS included death from any cause whereas for BCSS, deaths from breast cancer (coded as ICD-10 C50) were events of interest and deaths from other causes were censored at date of occurrence. Women without an event of interest were censored either at date of last information or end of 2009. Median follow-up time was calculated as time between diagnosis and the event of interest or censoring using the reverse Kaplan--Meier estimation ([@bib27]).

Statistical analysis
--------------------

Differences in baseline characteristics between deceased and non-deceased patients were tested using the *χ*^2^-statistic. The Kruskal--Wallis test was used to evaluate differences in the levels of enterolignans and lignan-rich foods between deceased and non-deceased patients. Spearman\'s correlation coefficients were used to correlate enterolignan intake with other dietary intake variables.

Cox proportional hazards models were used to estimate hazard ratios (HRs) for OS and BCSS, and their 95% confidence intervals (CIs) associated with enterolignans and fibre (in quintiles) using the lowest quintile as reference group. For the assessment of seed intake and prognosis, non-consumers were used as the reference category, and were compared with low consumers (intake below median consumption of the consumers) and high consumers (intake above and equal to median consumption of the consumers). Total bread (white, brown, and whole-grain), vegetable, and fruit intake were categorised into tertiles using the lowest tertile as reference group.

All analyses were stratified by age at diagnosis (in 1-year categories) and adjusted for the established prognostic factors tumour size (\<2 cm, 2--5 cm, ⩾5 cm, growth into chest wall, neoadjuvant chemotherapy-treated carcinoma, *in situ* carcinoma), nodal status (0, 1--3, 4--9, ⩾10, neoadjuvant chemotherapy-treated carcinoma, *in situ* carcinoma), metastasis (yes, no, *in situ* carcinoma), grade (1+2, 3+4, *in situ* carcinoma, neo-adjuvant chemotherapy-treated carcinoma), and ER/progesterone receptor (PR) status (*in situ* carcinoma, ER+/PR+, ER+/PR− or ER−/PR+, ER−/PR−, neoadjuvant chemotherapy-treated carcinoma). Further covariates for the multivariable regression analyses were determined using a backward elimination procedure based on *P*\<0.05 in the likelihood ratio test for the covariate or a \>10% change in HR for variable of interest. Thus, the models additionally included breast cancer detection type (physician-detected by clinical examination/mammography/ultrasound, self-detected by palpation/secretion/pain), use of menopausal hormone therapy at diagnosis (current, never/past), diabetes (yes, no), and study centre (Hamburg and RNK). Additionally, energy intake (kcal day^--1^, continuous) was included as a confounder in the multivariable regression models. The HER2-neu status, cardiovascular diseases, alcohol consumption, smoking habits, occupational status, type of surgery, phyto-oestrogen supplementation, adult BMI, physical activity, and further dietary variables (i.e., vitamin C, fat, carbohydrate, protein, bread, vegetable, and fruit intake), as well as hormonal, chemo-, and radiotherapy did not affect the risk estimates in the Cox models. Potential confounding by fibre was assessed by additional adjustment of the models of enterolignans for dietary fibre intake (continuous). Similarly, the model for dietary fibre was additionally adjusted for enterolactone levels (continuous). Additionally, subgroup analyses by low and high dietary fibre intake (\<median *vs* ⩾median) were performed. Tests for trend of the HRs were performed using continuous values of the variables.

To assess the functional form of the continuous variables in the multivariable Cox models, fractional polynomials were applied. The models with the best --2 log likelihoods were selected ([@bib24]), resulting in a linear association between the log HR and exposure variables for OS and BCSS. The test of Grambsch and Therneau ([@bib10]) was used to test the proportional hazards assumption and was found to hold for all analyses.

Effect modification was evaluated using the Q-statistic. Sensitivity analyses were performed by median time between diagnosis of breast cancer and date of FFQ completion, and by exclusion of phyto-oestrogen (isoflavone-containing) supplement users. Moreover, a subgroup analysis was conducted for patients with early-stage breast cancer (stage I--IIIa). Possible effect modification was assessed using analyses stratified by ER status of the tumour (positive *vs* negative), ER/PR status of the tumour (ER- or PR-positive *vs* ER-/PR-negative), and menopausal hormone therapy use at diagnosis (current *vs* past/never).

For all analyses, two-sided *P*-values \<0.05 were considered significant. No adjustment for multiple testing was performed because of the exploratory character of this study. All analyses were performed using R version 2.9.2 (R Development Core Team, Vienna, Austria) and SAS version 9.2 (SAS Institute, Cary, NC, USA).

Results
=======

Baseline characteristics
------------------------

Selected baseline characteristics of postmenopausal breast cancer patients are presented in [Table 1](#tbl1){ref-type="table"}. Median age at diagnosis of the patients was 63 years (interquartile range=9 years). Compared with the non-deceased patients, those who died within the follow-up period were older, were more likely to have higher adult BMI, larger tumours, more lymph node involvement, metastases, higher grade, ER-/PR-negative tumours, diabetes, self-detected tumours, and HT use at diagnosis. Deceased patients also had significantly lower dietary intake of sunflower-/pumpkinseeds, fibre, vegetables, and fruit, as well as lower exposure to estimated enterolignans compared with non-deceased patients (all *P*\<0.05; [Table 2](#tbl2){ref-type="table"}).

Total estimated enterolignans correlated positively with dietary sunflower-/pumpkinseed and sesame/flaxseed intake (correlation of 0.27 and 0.26, respectively), and with fibre intake (correlation of 0.73). Patients with higher enterolignan exposure had higher energy, carbohydrates, protein, fat, potato, bread, vegetable, and fruit intake (data not shown).

Prognostic association of enterolignans and lignan-rich foods
-------------------------------------------------------------

During a median follow-up time of 6.4 years, a total of 321 deaths occurred, of which 235 were due to breast cancer. Further causes of death included other cancers (*n*=41), cardiovascular diseases (*n*=22), and other causes (*n*=23).

Higher estimated levels of enterolactone, enterodiol, and dietary fibre were associated with significantly reduced overall mortality, with significantly reduced adjusted HRs for the highest compared with the lowest quintile (HR=0.60, 95% CI=0.40--0.89, *P*~Trend~=0.02, HR=0.63, 95% CI=0.42--0.95, *P*~Trend~=0.02, and HR=0.52, 95% CI=0.32--0.82, *P*~Trend~=0.01, respectively; [Table 3](#tbl3){ref-type="table"}). Multivariable regression modelling using fractional polynomials confirmed linear associations between exposure variables and OS. Associations of enterolignans and fibre with BCSS were similar to that with OS; however, the HRs were not statistically significant.

Additional adjustment for dietary fibre intake in the assessments of estimated enterolignans with respect to OS did not substantially alter the associations; however, they became nonsignificant ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). The association of dietary fibre with overall mortality also became nonsignificant after adjustment for enterolactone ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). When differentiated according to median dietary fibre intake, higher levels of both enterolactone and enterodiol were still significantly associated with lower overall mortality for the low fibre intake but not high fibre intake group, although the HRs for the highest quintiles were nonsignificant (highest quintile for enterolactone HR=0.32, 95% CI=0.10--1.04, *P*~Trend~=0.03 and HR=1.25, 95% CI=0.44--3.58, *P*~Trend~=0.08, respectively, and enterodiol HR=0.48, 95% CI=0.21--1.07, *P*~Trend~=0.01 and HR=1.08, 95% CI=0.38--3.04, *P*~Trend~=0.05, respectively; [Table 4](#tbl4){ref-type="table"}).

For the lignan-rich foods, there was no trend in association by level of consumption although the HRs for low *vs* no consumption were significant for sunflower-/pumpkinseeds (0.74, 95% CI=0.55--0.99) and for sesame/flaxseeds (0.73, 95% CI=0.54--0.99; [Table 5](#tbl5){ref-type="table"}). There was no significant trend with increasing intake of any lignan-rich food (all *P*~Trend~\>0.1). No association between lignan-rich foods and BCSS was observed ([Table 5](#tbl5){ref-type="table"}).

Sensitivity analysis by median time between diagnosis and FFQ completion (168 days, interquartile range=414 days) showed no significant heterogeneity between risk estimates for the estimated enterolignans, fibre, and lignan-rich foods and OS (all *P*~heterogeneity~\>0.05). Exclusion of 19 phyto-oestrogen supplement users also did not alter the risk estimates for any variable in association with OS (data not shown).

In 2228 patients with early-stage (I--IIIa) disease, the HRs for overall mortality associated with estimated enterolignans, fibre, and lignan-rich foods were similar to that in the total study population (all *P*~heterogeneity~\>0.1). The reductions in HR associated with the highest compared with the lowest quintiles were stronger for estimated enterolactone (HR=0.49, 95% CI=0.30--0.80, *P*~Trend~=0.02), enterodiol (HR=0.56, 95% CI=0.35--0.91, *P*~Trend~=0.02), and fibre (HR=0.45, 95% CI=0.26--0.80, *P*~Trend~=0.01).

There was no significant heterogeneity in the associations with estimated enterolignans and fibre by ER status ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}), ER/PR status, and menopausal hormone therapy use at diagnosis (all *P*~heterogeneity~\>0.1; data not shown).

Discussion
==========

Our data provide first evidence that postmenopausal patients with higher levels of the estimated enterolignans, enterolactone and enterodiol, may have a significantly increased OS, which is independent of ER status of the tumour. Higher dietary fibre intake was also associated with a significantly better survival after breast cancer. In addition, the lower mortality associated with higher enterolignan levels in women with lower than median fibre intake provides some evidence for an effect of enterolignans, which is independent of fibre intake.

The estimation of enterolignan -- the bioactive forms in the human body -- using the method by [@bib30]), which is based on *in vitro* fermentation of various plant foods with human faecal bacteria, has several strengths. It indirectly accounts for all enterolignan precursors and covers the long-term exposure to enterolignans. Nevertheless, the results must be interpreted cautiously as the estimation does not account for intra- and inter-individual variation of gut bacteria and metabolism. Also, the estimation is based on data collected in the early 1990s but, to our knowledge, there are no other data available to estimate the intestinally produced amounts of enterolactone and enterodiol, and this approach was also used by a previous study ([@bib31]).

Dietary intake of bread, vegetables, and fruits, which are important sources of lignans, was not individually associated with breast cancer prognosis. Intake of seeds, which are rich sources of lignans ([@bib20]), was associated with a nonsignificantly decreased overall mortality, but there was no significant dose-response relationship. Of note is that seeds contain other food constituents, like *α*-linoleic acids (present in flaxseed), that have been shown to have anti-carcinogenic and anti-proliferative properties, which could render a protective effect ([@bib33]; [@bib6]).

So far, no other study has assessed the association between estimated enterolignans and breast cancer prognosis. Comparison of our findings with results on dietary lignan intake may not be appropriate. Nevertheless, in two smaller studies (each with ∼800 postmenopausal women) conducted in the United States, higher dietary lignan intake was associated with lower mortality after breast cancer in one ([@bib15]) but not in the other ([@bib8]). Lignan intake was very different in these studies -- one reporting a median intake of 245 *μ*g day^--1^ ([@bib15]) and the other reporting 10 times higher intake levels (0 to \>9 mg day^--1^) ([@bib8]). In line with our results, a recent Danish study observed a significantly increased survival with higher plasma enterolactone levels ([@bib19]).

Lignans have been found in high amounts in fibre-rich foods (e.g., cereals, wholegrains), and enterolactone concentrations were primarily explained by vegetable, rye, and fibre intake in Finnish men ([@bib18]). In our study, the primary sources of estimated enterolignans were intake of bread (white, brown, and wholegrain), vegetables, and fruits, which are also rich sources of fibre. Fibre intake could affect breast cancer risk by several mechanisms, including stimulation of the intestinal microflora, reduction of the enterohepatic oestrogen circulation, and thereby reduction of oestrogen concentrations in the body ([@bib1]; [@bib28]). Additionally, increased fibre intake was found to be related to lower serum oestradiol levels in women with breast cancer ([@bib23]).

To account for potential confounding by fibre, we adjusted the multivariable regression models for estimated enterolignans and OS by fibre intake. High levels of estimated enterolignans were no longer significantly associated with overall mortality, probably because of their high correlation with fibre, which may have introduced collinearity in the multivariable models. Also, the association between dietary fibre and overall survival was no longer significant after adjustment for enterolactone. Adjustment for fibre intake was not found to affect the association of lignan intake with postmenopausal breast cancer risk in a study conducted in France ([@bib31]). However, the observation of a significant association of estimated enterolignans with a better prognosis in those with low dietary fibre intake strengthens the hypothesis that enterolignans may influence the prognosis of postmenopausal breast cancer independent of fibre intake. Furthermore, it has been suggested that high lignan intake might be an indicator of a healthy lifestyle ([@bib28]). However, adjustment for lifestyle factors including physical activity, BMI, alcohol, and smoking did not affect the associations observed for enterolignans.

No significant effect heterogeneity by ER status of the tumours and menopausal hormone therapy use at diagnosis was observed for the association of estimated enterolignans and fibre with overall mortality, which is in line with the results of another study on dietary lignans and prognosis ([@bib8]). Therefore, hormone-dependent and -independent mechanisms of action might be involved in the observed association with enterolignans. Enterolignans are able to bind to ERs, thereby preventing endogenous oestrogens from binding and inhibiting tumour growth stimulation ([@bib3]). In animal studies, several hormone-independent mechanisms have been suggested, such as inhibition of angiogenesis, tumour growth, and metastasis, as well as stimulation of apoptosis ([@bib22]; [@bib26], [@bib25]). Moreover, an intervention with flaxseed in postmenopausal breast cancer patients resulted in an increased apoptosis and a decrease of tumour biological markers in tumour tissues ([@bib29]).

The strength of our study was the large population-based patient sample with complete follow-up and verification of causes of death using death certificates as well as the consideration of all relevant prognostic factors. Sensitivity analyses were performed, which showed that results were not affected by time of diagnosis and FFQ completion. Additionally, fibre intake, enterolignan levels, and lignan-rich foods (except for the seeds) were estimated using a validated dietary questionnaire. Thereby, a broad spectrum of dietary lignan sources was addressed. The FFQ assessed dietary habits over the entire 12 months before diagnosis and, thus, captures the long-term situation of enterolignan exposure.

In the interpretation of our results, we also need to address some limitations. The assessment of dietary intake may be subject to measurement errors that are not only due to recall bias but also to the estimation using food-composition databases, which may not be complete for the whole range of foods consumed. Dietary changes after diagnosis, which could have contributed to survival, were not accounted for in this analysis. Although we collected comprehensive data and assessed many possible confounding factors, residual confounding could not be entirely ruled out. Also, sample size was limited in subgroups and therefore results must be interpreted cautiously.

In conclusion, we found some evidence for a better prognosis in postmenopausal breast cancer patients who have high estimated enterolignan and dietary fibre exposures. The associations of estimated enterolignans with survival were independent of ER status of the tumour and may, in part, be independent of dietary fibre intake. However, further investigations on enterolignans measured in serum or urine and breast cancer prognosis are warranted to confirm our results and to disentangle the possible mechanisms involved.
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###### Distribution of sociodemographic variables and prognostic factors for 2653 postmenopausal breast cancer patients by vital status

                                                    **Alive**   **Deceased**   ***χ*^2^**            
  ------------------------------------------------- ----------- -------------- ------------ -------- --------
  *Age at diagnosis (years)*                                                                         \<0.01
   50--54                                           170         7.3            22           6.9       
   55--59                                           541         23.2           73           22.7      
   60--65                                           760         32.6           80           24.9      
   65--70                                           622         26.7           88           27.4      
   70--74                                           239         10.3           58           18.1      
                                                                                                      
  *Adult BMI (kg* *m*^*--2*^)                                                                        \<0.01
   \<18.5                                           66          2.8            10           3.1       
   18.5--25                                         1757        75.3           212          66.0      
   25--30                                           438         18.8           80           24.9      
   \>30                                             71          3.0            19           5.9       
                                                                                                      
  *Tumour size*                                                                                      \<0.01
   \<2 cm                                           1296        55.6           94           29.3      
   2--5 cm                                          715         30.7           141          43.9      
   ⩾5 cm                                            61          2.6            22           6.9       
   Growth into chest wall                           36          1.5            28           8.7       
   *In situ*                                        155         6.7            4            1.3       
   Neoadjuvant chemotherapy                         64          2.7            24           7.5       
   Missing                                          5           0.2            8            2.5       
                                                                                                      
  *Nodal status*                                                                                     \<0.01
   0                                                1507        64.6           121          37.7      
   1--3                                             455         19.5           95           29.6      
   4--9                                             99          4.3            31           9.7       
   ⩾10                                              48          2.1            38           11.8      
   *In situ*                                        155         6.7            4            1.3       
   Neoadjuvant chemotherapy                         64          2.7            24           7.5       
   Missing                                          4           0.2            8            2.5       
                                                                                                      
  *Metastasis*                                                                                       \<0.01
   No                                               2145        92.0           263          81.9      
   Yes                                              23          1.0            48           15.0      
   *In situ*                                        155         6.7            4            1.3       
   Missing                                          9           0.4            6            1.9       
                                                                                                      
  *Grade*                                                                                            \<0.01
   G1+G2                                            1589        68.1           148          46.1      
   G3+G4                                            517         22.2           143          44.6      
   *In situ*                                        155         6.7            4            1.3       
   Neoadjuvant chemotherapy                         64          2.7            24           7.5       
   Missing                                          7           0.3            2            0.6       
                                                                                                      
  *ER/PR status*                                                                                     \<0.01
   ER+/PR+                                          1391        59.7           149          46.4      
   ER+/PR− or ER−/PR+                               411         17.6           59           18.4      
   ER−/PR−                                          304         13.0           84           26.2      
   *In situ*                                        155         6.7            4            1.3       
   Neoadjuvant chemotherapy                         64          2.7            24           7.5       
   Missing                                          7           0.3            1            0.3       
                                                                                                      
  *HER2-neu status*                                                                                  \<0.01
   Positive                                         360         15.4           72           22.4      
   Negative                                         1528        65.5           195          60.8      
   *In situ*                                        155         6.7            4            1.3       
   Neoadjuvant chemotherapy                         64          2.7            24           7.5       
   Missing                                          225         9.7            26           8.1       
                                                                                                      
  *Breast cancer detection type*                                                            \<0.01    
   Self-detected                                    1147        49.2           241          75.1      
   Physician-detected                               1175        50.4           80           24.9      
   Missing                                          10          0.4            0            0.0       
                                                                                                      
  *Menopausal hormone therapy use at diagnosis*                                             \<0.01    
   No/past                                          1151        49.4           226          70.4      
   Yes                                              1165        50.0           93           29.0      
   Missing                                          16          0.7            2            0.6       
                                                                                                      
  *Diabetes*                                                                                         \<0.01
   No                                               2158        92.5           278          86.6      
   Yes                                              171         7.3            42           13.1      
   Missing                                          3           0.1            1            0.3       
                                                                                                      
  *Cardiovascular disease*                                                                           \<0.01
   No                                               1197        51.3           131          40.8      
   Yes                                              1135        48.7           190          59.2      
                                                                                                      
  *Surgery type*                                                                                     \<0.01
   Breast ablation                                  263         11.3           76           23.7      
   Breast conservation                              775         33.2           76           23.6      
   Missing                                          1294        55.5           169          52.7      
                                                                                                      
  *Leisure time physical activity (since age 50)*                                           0.38      
   \<28 MET h per week                              608         26.1           92           28.7      
   ⩾28 MET h per week                               1701        72.9           229          71.3      
   Missing                                          23          1.0            0            0.0       
                                                                                                      
  *Phyto-oestrogen supplement use*                                             0.16                   
   No                                               2313        99.2           321          100.0     
   Yes                                              19          0.8            0            0.0       
                                                                                                      
  *Smoking*                                                                                          0.75
   Never                                            1276        54.7           175          54.5      
   Former                                           648         27.8           85           26.5      
   Current                                          408         17.5           61           19.0      
                                                                                                      
  *Alcohol (g* *day*^*--1*^)                                                                         0.53
   0                                                316         13.6           42           13.1      
   \<19                                             1719        73.7           231          72.0      
   ⩾19                                              296         12.7           48           15.0      
   Missing                                          1           0.0            0            0.0       

Abbreviations: BMI=body mass index; ER=oestrogen receptor; HER2-neu=human epidermal growth factor receptor 2; PR=progesterone receptor; MET=metabolic equivalent value.

###### Consumption levels of estimated enterolignans, dietary fibre, and lignan-rich foods by vital status

  **Item**                               **Vital status (*N*)**   **Mean**   **Median**   **IQR**   ***P* Kruskal--Wallis**
  -------------------------------------- ------------------------ ---------- ------------ --------- -------------------------
  Enterolactone (*μ*g day^--1^)          Alive (2332)             312.5      279.4        190.5     \<0.001
                                         Deceased (321)           280.5      246.7        166.6      
                                                                                                     
  Enterodiol (*μ*g day^--1^)             Alive (2332)             465.3      373.3        296.5     \<0.001
                                         Deceased (321)           403.8      325.6        212.8      
                                                                                                     
  Fibre (g day^--1^)                     Alive (2332)             20.8       20.0         8.1       0.04
                                         Deceased (321)           20.0       19.6         8.2        
                                                                                                     
  Sunflower-/pumpkinseeds (g day^--1^)   Alive (2332)             3.4        0.2          2.1       0.003
                                         Deceased (321)           2.3        0.2          2.1        
                                                                                                     
  Sesame/flaxseeds (g day^--1^)          Alive (2332)             2.5        0.0          1.4       0.05
                                         Deceased (321)           1.7        0.0          1.4        
                                                                                                     
  Bread (g day^--1^)                     Alive (2332)             131.9      123.8        73.5      0.29
                                         Deceased (321)           136.4      130.7        76.5       
                                                                                                     
  Vegetables (g day^--1^)                Alive (2332)             135.8      119.1        72.8      0.05
                                         Deceased (321)           127.1      113.2        73.1       
                                                                                                     
  Fruit (g day^--1^)                     Alive (2332)             165.3      130.3        117.2     0.03
                                         Deceased (321)           155.5      106.5        106.9      

Abbreviation: IQR=interquartile range.

###### Multivariable[a](#t3-fn2){ref-type="fn"} HRs of estimated enterolignans, dietary fibre, and overall and breast cancer-specific mortality of postmenopausal breast cancer patients

                                                                  **Overall mortality**   **Breast cancer-specific mortality**                                                    
  ----------------- --------------------------------------- ----- ----------------------- -------------------------------------- -------------- ------ ---- ------ -------------- ------
  *Enterolactone*                                                                                                                                                                 
   1                146.0 (41.9)                            530   84                      1.00                                        Ref              59   1.00        Ref        
   2                211.9 (28.6)                            531   74                      0.87                                    (0.62--1.22)         54   0.88    (0.59--1.32)   
   3                274.3 (32.8)                            530   53                      0.69                                    (0.48--1.00)         38   0.77    (0.50--1.20)   
   4                360.7 (50.4)                            530   62                      0.91                                    (0.63--1.32)         48   1.18    (0.76--1.82)   
   5                502.0 (142.5)                           532   48                      0.60                                    (0.40--0.89)  0.02   36   0.69    (0.43--1.10)  0.35
                                                                                                                                                                                   
  *Enterodiol*                                                                                                                                                                    
   1                186.9 (59.8)                            530   76                      1.00                                        Ref              54   1.00        Ref        
   2                279.8 (39.5)                            531   76                      0.95                                    (0.67--1.33)         53   0.92    (0.61--1.39)   
   3                366.8 (50.2)                            530   70                      0.97                                    (0.69--1.37)         53   1.07    (0.72--1.61)   
   4                499.9 (89.0)                            531   53                      0.79                                    (0.54--1.15)         37   0.84    (0.53--1.33)   
   5                857.5 (368.6)                           531   46                      0.63                                    (0.42--0.95)  0.02   38   0.81    (0.51--1.29)  0.40
                                                                                                                                                                                   
  *Fibre*                                                                                                                                                                         
   1                13.3 (3.0)[b](#t3-fn3){ref-type="fn"}   530   80                      1.00                                        Ref              55   1.00        Ref        
   2                16.9 (1.5)[b](#t3-fn3){ref-type="fn"}   531   62                      0.71                                    (0.50--1.02)         42   0.74    (0.48--1.16)   
   3                19.9 (1.5)[b](#t3-fn3){ref-type="fn"}   531   68                      0.68                                    (0.47--0.97)         56   0.82    (0.54--1.26)   
   4                23.2 (1.9)^b^                           530   53                      0.64                                    (0.43--0.95)         41   0.71    (0.44--1.14)   
   5                28.9 (5.7)^b^                           531   53                      0.52                                    (0.32--0.82)  0.01   41   0.64    (0.37--1.11)  0.01

Abbreviations: CI=confidence interval; ER=oestrogen receptor; HR=hazard ratio; IQR=interquartile range; PR=progesterone receptor; Q=quantile.

Stratified by age at diagnosis. Adjusted for tumour size, nodal status, metastasis, grade, ER/PR status, breast cancer detection type, diabetes, menopausal hormone therapy use at diagnosis, study centre, and energy intake.

In g day^--1^.

###### Multivariable[a](#t4-fn2){ref-type="fn"} HRs of enterolignans and overall mortality of postmenopausal breast cancer patients by dietary fibre intake

                    **Low fibre intake**[b](#t4-fn3){ref-type="fn"}    **High fibre intake**[b](#t4-fn3){ref-type="fn"}                               
  ----------------- ------------------------------------------------- -------------------------------------------------- ------ ------ -------------- ------
  *Enterolactone*                                                                                                                                     
   1                1.00                                                                     Ref                                1.00        Ref        
   2                0.82                                                                 (0.56--1.20)                           2.07    (0.67--6.46)   
   3                0.65                                                                 (0.40--1.07)                           1.39    (0.48--4.03)   
   4                0.84                                                                 (0.44--1.58)                           2.04    (0.71--5.18)   
   5                0.32                                                                 (0.10--1.04)                    0.03   1.25    (0.44--3.58)  0.08
                                                                                                                                                       
  *Enterodiol*                                                                                                                                        
   1                1.00                                                                     Ref                                1.00        Ref        
   2                0.91                                                                 (0.63--1.33)                           1.48    (0.50--4.42)   
   3                0.90                                                                 (0.57--1.42)                           1.50    (0.54--4.16)   
   4                0.39                                                                 (0.16--0.99)                           1.58    (0.57--4.37)   
   5                0.48                                                                 (0.21--1.07)                    0.01   1.08    (0.38--3.04)  0.05

Abbreviations: CI=confidence interval; ER=oestrogen receptor; HR=hazard ratio; PR=progesterone receptor; Q=quantile.

Stratified by age at diagnosis. Adjusted for tumour size, nodal status, metastasis, grade, ER/PR status, breast cancer detection type, diabetes, menopausal hormone therapy use at diagnosis, study centre, and energy intake.

Below *vs* equal to or above the median dietary fibre intake.

###### HRs of phyto-oestrogen-rich foods and overall and breast cancer-specific mortality of postmenopausal breast cancer patients

  **Food item**            **Survival measure**                                                          **No consumption**        **Low consumption**[a](#t5-fn2){ref-type="fn"}   **High consumption**[a](#t5-fn2){ref-type="fn"}   ***P*~Trend~**
  ------------------------ ---------------------- ------------------------------------------------------ ------------------------- ------------------------------------------------ ------------------------------------------------- ----------------
  Sunflower/pumpkinseeds   Overall mortality      *N*/deaths (median intake)                             1126/157 (0 g day^--1^)   747/82 (0.4 g /day^--1^)                         780/82 (4.5 g day^--1^)                            
                                                  Multivariable HR (95% CI)[b](#t5-fn3){ref-type="fn"}   1.00 (Ref)                0.74 (0.55--0.99)                                0.87 (0.66--1.15)                                 0.17
                           BC mortality           Multivariable HR (95% CI)[b](#t5-fn3){ref-type="fn"}   1.00 (Ref)                0.88 (0.63--1.24)                                1.12 (0.79--1.57)                                 0.35
                                                                                                                                                                                                                                       
  Sesame/flaxseeds         Overall mortality      *N*/deaths (median intake)                             1355/182 (0 g day^--1^)   591/57 (0.3 g /day^--1^)                         707/82 (3.6 g /day^--1^)                           
                                                  Multivariable HR (95% CI)[b](#t5-fn3){ref-type="fn"}   1.00 (Ref)                0.69 (0.50--0.95)                                0.90 (0.68--1.19)                                 0.26
                           BC mortality           Multivariable HR (95% CI)[b](#t5-fn3){ref-type="fn"}   1.00 (Ref)                0.75 (0.51--1.09)                                1.21 (0.87--1.68)                                 0.87
                                                                                                                                                                                                                                       
                                                                                                         **Tertile 1**             **Tertile 2**                                    **Tertile 3**                                      
  Bread                    Overall mortality      *N*/deaths (median intake)                             875/98 (80 g day^--1^)    902/118 (125 g day^--1^)                         876/105 (191 g day^--1^)                           
                                                  Multivariable HR (95% CI)[b](#t5-fn3){ref-type="fn"}   1.00 (Ref)                1.50 (1.12--2.01)                                1.31 (0.93--1.83)                                 0.07
                           BC mortality           Multivariable HR (95% CI)[b](#t5-fn3){ref-type="fn"}   1.00 (Ref)                1.38 (0.98--1.94)                                1.10 (0.74--1.63)                                 0.33
                                                                                                                                                                                                                                       
  Vegetables               Overall mortality      *N*/deaths (median intake)                             875/118 (79 g day^--1^)   902/100 (118 g day^--1^)                         876/103 (183 g day^--1^)                           
                                                  Multivariable HR (95% CI)[b](#t5-fn3){ref-type="fn"}   1.00 (Ref)                0.97 (0.72--1.30)                                1.09 (0.80--1.48)                                 0.56
                           BC mortality           Multivariable HR (95% CI)[b](#t5-fn3){ref-type="fn"}   1.00 (Ref)                0.86 (0.61--1.22)                                1.01 (0.70--1.46)                                 0.16
                                                                                                                                                                                                                                       
  Fruits                   Overall mortality      *N*/deaths (median intake)                             876/122 (79 g day^--1^)   902/104 (128 g day^--1^)                         876/95 (259 g day^--1^)                            
                                                  Multivariable HR (95% CI)[b](#t5-fn3){ref-type="fn"}   1.00 (Ref)                0.90 (0.68--1.20)                                0.84 (0.61--1.16)                                 0.80
                           BC mortality           Multivariable HR (95% CI)[b](#t5-fn3){ref-type="fn"}   1.00 (Ref)                0.90(0.64--1.27)                                 0.86 (0.59--1.25)                                 0.82

Abbreviations: BC=breast cancer-specific; CI=confidence interval; ER=oestrogen receptor; HR=hazard ratio; PR=progesterone receptor.

Low and high consumption defined by below and above/equal to median consumption of the consumers, respectively.

Stratified by age at diagnosis. Adjusted for tumour size, nodal status, metastasis, grade, ER/PR status, breast cancer detection type, diabetes, menopausal hormone therapy use at diagnosis, study centre, and energy intake.

^c^Stratified by age at diagnosis.
